Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleuce

Alex V. Mejia Garcia; Additional authors and institutional affiliations

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleuce

Alex V. Mejia Garcia, Additional authors and institutional affiliations

Baptist Health South Florida

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	136
State	Published - 2020

Disciplines

Medicine and Health Sciences

Cite this

@article{03ef68fedddc4a798ac0eaa0eab6abb7,

title = "Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleuce",

author = "\{Mejia Garcia\}, \{Alex V.\} and \{and institutional affiliations\}, \{Additional authors\}",

note = "IntroductionUse of the two commercially available anti CD19 chimeric antigen receptor T-cell (CAR T-cell) therapies in patients with relapsed and refractory (R/",

year = "2020",

language = "American English",

volume = "136",

journal = "Blood",

}

TY - JOUR

T1 - Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleuce

AU - Mejia Garcia, Alex V.

AU - and institutional affiliations, Additional authors

N1 - IntroductionUse of the two commercially available anti CD19 chimeric antigen receptor T-cell (CAR T-cell) therapies in patients with relapsed and refractory (R/

PY - 2020

Y1 - 2020

UR - https://ashpublications.org/blood/article/136/Supplement%201/38/473846/Resource-Utilization-and-Factors-Prolonging

M3 - Article

VL - 136

JO - Blood

JF - Blood

ER -

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleuce

Disciplines

Other files and links

Cite this